Yannic Danger
Impact in
- Immunology top 5%
- Psoriasis: Treatment and Pathogenesis
- IL-33, ST2, and ILC Pathways
- T-cell and B-cell Immunology
- Dermatology top 5%
- Dermatology and Skin Diseases
Papers in
- Immunology 10
- T-cell and B-cell Immunology 4
- Psoriasis: Treatment and Pathogenesis 3
- Immune Cell Function and Interaction 3
- Immunotherapy and Immune Responses 2
- Co-authors
- Sylvie Chevalier (6 shared papers)Hugues Gascan (7 shared papers)Elisa Ravon (3 shared papers)Laurence Preisser (2 shared papers)Emilie Vénéreau (2 shared papers)Jean‐Pierre Molès (1 shared paper)Jérôme Pène (1 shared paper)Hans Yssel (1 shared paper)
In The Last Decade
Yannic Danger
18 papers receiving 964 citations
Peers
Comparison fields: 5 of 79
- Immunology 445
- Dermatology 96
- Genetics 93
- Immunology and Allergy 34
- Hematology 63
Countries citing papers authored by Yannic Danger
This map shows the geographic impact of Yannic Danger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yannic Danger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yannic Danger more than expected).
Fields of papers citing papers by Yannic Danger
This network shows the impact of papers produced by Yannic Danger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yannic Danger. The network helps show where Yannic Danger may publish in the future.
Co-authors
The 25 scholars most cited alongside Yannic Danger, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2008 | 431 | |
| 2 | 2012 | 398 | |
| 3 | 2015 | 24 | |
| 4 | 2009 | 19 | |
| 5 | 2010 | 19 | |
| 6 | 2015 | 16 | |
| 7 | 2005 | 10 | |
| 8 | 2015 | 9 | |
| 9 | 2021 | 9 | |
| 10 | 2015 | 7 | |
| 11 | 2022 | 7 | |
| 12 | 2020 | 7 | |
| 13 | 2004 | 6 | |
| 14 | 2019 | 6 | |
| 15 | 2012 | 6 | |
| 16 | 2024 | 3 | |
| 17 | Design of cocaethylene and cocaine conjugates to produce highly selective polyclonal antibodies. | 2006 | 2 |
| 18 | 2018 | 2 | |
| 19 | 2025 | 0 |
About Yannic Danger
Yannic Danger is a scholar working on Immunology, Molecular Biology, Oncology, Toxicology and Hematology, having authored 19 papers that have together received 981 indexed citations. Recurring topics across this work include T-cell and B-cell Immunology (4 papers), Blood groups and transfusion (3 papers), Forensic Toxicology and Drug Analysis (3 papers), Psoriasis: Treatment and Pathogenesis (3 papers), Cytokine Signaling Pathways and Interactions (3 papers), Immune Cell Function and Interaction (3 papers), Platelet Disorders and Treatments (2 papers) and Immunotherapy and Immune Responses (2 papers). The work is most often cited by research in Immunology (445 citations), Dermatology (96 citations), Genetics (93 citations), Immunology and Allergy (34 citations) and Hematology (63 citations). Yannic Danger has collaborated with scholars based in France, Canada and Mali. Frequent co-authors include Sylvie Chevalier, Hugues Gascan, Elisa Ravon, Laurence Preisser, Emilie Vénéreau, Jean‐Pierre Molès, Jérôme Pène, Hans Yssel, Soufiane Ghannam and Dominique Heymann. Their work appears in journals such as Journal of Biological Chemistry, Transfusion, Blood Advances, iScience and Journal of Molecular Medicine.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.